Progyny (NASDAQ:PGNY) Price Target Raised to $33.00

Progyny (NASDAQ:PGNY) had its target price boosted by Citizens Jmp from $31.00 to $33.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a market outperform rating on the stock.

PGNY has been the topic of a number of other research reports. Citigroup restated an “outperform” rating on shares of Progyny in a research report on Tuesday. BTIG Research upped their price target on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. increased their price target on Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, August 21st. Finally, Wall Street Zen downgraded Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.36.

Progyny Trading Down 0.1%

Shares of NASDAQ PGNY opened at $27.08 on Tuesday. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 1.87 and a beta of 0.99. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The stock has a 50-day moving average price of $28.76 and a two-hundred day moving average price of $23.99.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $350.51 million for the quarter, compared to the consensus estimate of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, sell-side analysts predict that Progyny will post 1.25 earnings per share for the current year.

Progyny declared that its Board of Directors has initiated a share repurchase plan on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Progyny

Institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Progyny during the fourth quarter valued at $25,000. Public Employees Retirement System of Ohio acquired a new stake in Progyny in the second quarter valued at $29,000. Nykredit A S acquired a new stake in Progyny in the second quarter valued at $38,000. Hantz Financial Services Inc. increased its holdings in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares during the period. Finally, IFP Advisors Inc raised its position in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.